EGFR and head and neck cancer: Currently, a global clinical trial in phase 3 is underway to investigate the efficacy of ASP-1929, an mAb-IR700 that targets the epidermal growth factor receptor (EGFR), in patients with recurrent or inoperable head and neck cancer (NCT03769506).